BRIGHTCOVE
18.8.2020 15:02:14 CEST | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the world’s leading video technology platform, today published the Brightcove Q2 2020 Global Video Index Entertainment and Media Edition , which found that OTT streaming of entertainment content continued to dominate, even as governments began loosening stay-at-home restrictions. The data suggests that consumers’ media consumption habits may be permanently shifting away from linear TV, cementing streaming as the go-to choice for entertainment viewing.
Brightcove’s Q2 2020 Global Video Index analyzes hundreds of billions of recent data points from Brightcove’s customers globally to provide insights into how viewers are watching video content. The Q2 data shows that consumption of news and entertainment content nearly doubled (40%) from Q1 (23%) – a significant finding considering Q2 typically sees slower growth in video viewing compared to Q1. Looking at the first half of 2020 compared to 2019, the number of views overall is up more than 30%.
“Consumers in Europe continue to remain glued to their smartphones as we’ve seen mobile consumption surge for two consecutive quarters now,” said Jim O’Neill, Principal Analyst and Author of Brightcove’s Global Video Index. “This, in addition to video views on connected TVs continuing to grow, indicates consumers increasingly are turning to streaming devices to view entertainment content. This shift in consumption will only strengthen as connected TVs inevitably replace computers as the second preferred device for consumption – following mobile.”
Where consumers choose to view their content is also shifting. Connected TVs (CTVs) saw the most growth in Q2 (160% year-over-year), indicating a resurgence in larger screens as the viewing medium of choice for entertainment.
Other notable findings from the Brightcove Q2 2020 Global Video Index that are specific to Europe include:
- Consumption peaked despite regions reopening. Video views were up 52% in Q2.
- Smartphones are continuing to see spikes in consumption. Views on mobile devices increased by 69%, following Q1 in which mobile views more than doubled. Smartphones were also dominant across all content lengths in Q2.
- CTVs saw a surge in use. Video views on CTVs were up 42% in Q2; 45% in April, 37% in May, and 44% in June. For the first six months of the year, views on CTVs grew 49%, the second biggest gain among devices. CTV viewers also watched content more than 3x as long as on any other device.
“2020 has become video’s evolutionary moment, and streaming entertainment video content is one area where we will continue to see growth,” said Jeff Ray, Brightcove CEO. “The crisis has impacted people at an emotional and financial level, making the need for human connection through video content more crucial than ever. We’re seeing this play out with the rise of streaming services subscriptions, indicating that the future of entertainment consumption lies in connected and mobile devices – linear television could soon be of the past.”
To download the complete Brightcove Q2 2020 Global Video Index Entertainment and Media Edition inclusive of all data, visit: https://www.brightcove.com/en/video-index
To learn more about this quarter’s findings, tune into an exclusive webinar with Jim O’Neill on September 15th. To register, visit: https://get.brightcove.com/global-video-index-2020-q2/
About the Global Video Index
Brightcove’s Global Video Index assesses more than 400 billion anonymized data points from Brightcove’s thousands of customers each quarter, drawing industry insights that can help guide strategic and tactical decisions for businesses of all sizes.
About Brightcove Inc. (NASDAQ: BCOV)
We are the people behind the world’s leading video technology platform. With our award-winning technology and services, we help organizations in more than 70 countries meet business challenges and create strategic opportunities by inspiring, entertaining, and engaging their audiences through video.
Since Brightcove was established in 2004, we have consistently pushed boundaries to create a platform for people who are serious about video: one that is robust, scalable, and intuitive. Benefiting from a global infrastructure, unrivalled customer support, an extensive partner ecosystem, and relentless investment in R&D, Brightcove video sets the standard for professional grade video management, distribution, and monetization. To learn more, visit www.brightcove.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005243/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom